Page 8 - Clinical-Medical Solution for Clinical Chemistry
P. 8
LAAN-A-LM-E123
Application Liquid Chromatograph Mass Spectrometry
News Simultaneous Analysis of Antiarrhythmic Drugs in
Human Blood Plasma Using the Fully Automated
No. C153 Sample Preparation LC/MS/MS System
During drug treatment with drugs that pose Analysis of Antiarrhythmic Drugs in Blood
administration management difficulties, such as drugs Plasma with Fully Automated Pretreatment
with a narrow therapeutic range or drugs with a fine Pretreatment of blood plasma samples for analysis
line between toxicity and effectiveness, the blood normally requires a process that involves
concentration of drugs in patients is measured to deproteinization by adding an organic solvent,
determine the optimal dose and method of followed by centrifugal separation of solid
administration for individuals based on components and supernatant isolation. With the fully
pharmacokinetic and pharmacodynamic analysis. automated sample preparation LC/MS/MS system,
Application News No. C123 introduced an these preparatory steps are done automatically just by
investigation into optimizing the analysis workflow setting a blood collection tube after blood plasma
including pretreatment by using the fully automated separation, and LC/MS/MS analysis is continuously
sample preparation LC/MS/MS system that comprises performed (Fig. 1). Pretreatment of the next sample can
the CLAM-2000 fully automated LCMS sample also be performed in parallel with LC/MS/MS analysis,
preparation unit and a high performance liquid which can greatly reduce the time required for each
chromatograph mass spectrometer.
sample analysis.
This article introduces a study which achieves a fast and In this analysis example, a per-sample cycle time of 7
simultaneous analysis workflow of six antiarrhythmic
drugs with the fully automated sample preparation minutes was achieved from blood plasma
pretreatment to the simultaneous analysis of six
LC/MS/MS system.
antiarrhythmic drugs and metabolites using LC/MS/MS
T. Tsukamoto, D. Kawakami
(Table 1 and Fig. 2).
Pretreatment Workflow of Blood Plasma Samples
Table 1 Antiarrhythmic Drugs and Metabolites (x10,000,000)
1: Amiodarone
MRM 1.25 2: Desethylamiodarone
Molecular
Compound Transition 3: Bepridil
Formula 4: Flecainide 1
m/z 1.00 5: Pilsicainide
6: Cibenzoline 2
Amiodarone C25H29I2NO3 646.0 > 58.1 7: Mexiletine 3
0.75
Desethylamiodarone * C23H25I2NO3 618.0 > 72.1
Bepridil C24H34N2O 367.1 > 84.1 0.50 5 4
Flecainide C17H20F6N2O3 415.0 > 301.0
6
Pilsicainide C17H24N2O 272.9 > 110.1 0.25
7
Cibenzoline C18H18N2 262.9 > 115.0
0.00
Mexiletine C11H17NO 180.1 > 58.0
0.0 0.5 1.0 1.5 2.0 2.5 min
Mass Chromatograms of Human Blood Plasma
with Standard Additives
